Releasefaa9345b-168e-47b5-8d3e-2b4b4a581492_2150864.pdf Cranbury, NJ – July 27, 2015 — Oncobiologics, Inc.,announced the closing of a $31 million financing. Proceeds will be used to support continued development and expansion of the company’s proprietary BioSymphony™ biosimilar platform and advancement of its preclinical and clinical programs. The investment round was led by new investor, Perceptive Advisors. Participating new investors …
Adaptimmune raises $104 mln to develop immune-system cancer drugs
LONDON, Sept 25 (Reuters) – British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells. The Oxford-based private company plans to use the money to advance its programmes to clinical trials against multiple types of cancer, it said on …
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Investor syndicate includes leading biotech and mutual funds. HOUSTON–BUSINESS WIRE–Bellicum Pharmaceuticals, Inc., a biotechnology company focused on developing safer and more effective cellular immunotherapies, today announced the successful completion of a $55M Series C financing. The funding will be used to expand the clinical evaluation of Bellicum’s stem cell transplant, chimeric antigen receptor (CAR) T …
+1 212.937.4970